Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2080
Revised: May 10, 2024
Accepted: June 7, 2024
Published online: July 27, 2024
Processing time: 144 Days and 3.6 Hours
Currently, endoscopic retrograde cholangiopancreatography (ERCP) plus laparoscopic cholecystectomy (LC) is the main treatment for cholecystolithiasis com
To determine the clinical efficacy of LC plus cholangioscopy for cholecystolithiasis combined with choledocholithiasis.
Patients (n = 243) with cholecystolithiasis and choledocholithiasis admitted to The Affiliated Haixia Hospital of Huaqiao University (910th Hospital of Joint Logistic Support Force) between January 2019 and December 2023 were included in the study; 111 patients (control group) underwent ERCP + LC and 132 patients (observation group) underwent LC + laparoscopic common bile duct exploration (LCBDE). Surgical success rates, residual stone rates, complications (pancreatitis, hyperamylasemia, biliary tract infection, and bile leakage), surgical indicators [intraoperative blood loss (IBL) and operation time (OT)], recovery indices (postoperative exhaust/defecation time and hospital stay), and serum inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were compared.
No significant differences in surgical success rates and residual stone rates were detected between the observation and control groups. However, the complication rate, IBL, OT, postoperative exhaust/defecation time, and hospital stays were significantly reduced in the observation group compared with the control group. Furthermore, CRP, TNF-α, and IL-6 Levels after treatment were reduced in the observation group compared with the levels in the control group.
These results indicate that LC + LCBDE is safer than ERCP + LC for the treatment of cholecystolithiasis combined with choledocholithiasis. The surgical risks and postoperative complications were lower in the observation group compared with the control group. Thus, patients may recover quickly with less inflammation after LCBDE.
Core Tip: Choledocholithiasis occurs in 10%–18% of patients with cholecystolithiasis. At present, the main treatment for cholecystolithiasis combined with choledocholithiasis is endoscopic retrograde cholangiopancreatography (ERCP) combined with laparoscopic cholecystectomy (LC). However, this treatment has several disadvantages. In this study, the treatment outcomes of patients with cholecystolithiasis combined with choledocholithiasis were compared after LC + laparoscopic common bile duct exploration (LCBDE) vs ERCP + LC + LCBDE. Clinical efficacy was better ERCP + LC, patient recovery was accelerated, and surgical risks, postoperative complications, and serum inflammatory factors were lower after LC + LCBDE compared with ERCP + LC.